

S 3180

Responsibility in Drug Advertising Act of 2020

Congress: 116 (2019–2021, Ended)

Chamber: Senate

Policy Area: Health

Introduced: Jan 9, 2020

Current Status: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Latest Action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Jan 9, 2020)

Official Text: <https://www.congress.gov/bill/116th-congress/senate-bill/3180>

Sponsor

Name: Sen. King, Angus S., Jr. [I-ME]

Party: Independent • **State:** ME • **Chamber:** Senate

Cosponsors

No cosponsors are listed for this bill.

Committee Activity

Committee	Chamber	Activity	Date
Health, Education, Labor, and Pensions Committee	Senate	Referred To	Jan 9, 2020

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
116 HR 4106	Identical bill	Jul 31, 2019: Referred to the Subcommittee on Health.
116 HR 2452	Related bill	May 31, 2019: Referred to the Subcommittee on Courts, Intellectual Property, and the Internet.

Summary (as of Jan 9, 2020)

Responsibility in Drug Advertising Act of 2020

This bill prohibits direct-to-consumer advertising of a drug in the first three years after the drug's approval. The Food and Drug Administration may (1) waive the third year of this prohibition for a drug if direct-to-consumer advertising of the drug would have an affirmative value to public health, or (2) extend the prohibition if the drug has significant adverse health effects.

Actions Timeline

- **Jan 9, 2020:** Introduced in Senate
- **Jan 9, 2020:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.